American Portfolios Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$562K Buy
17,284
+12
+0.1% +$495 0.02% 599
2022
Q2
$680K Sell
17,272
-140
-0.8% -$7.49K 0.03% 550
2022
Q1
$1.22M Buy
17,412
+2,458
+16% +$180K 0.04% 426
2021
Q4
$1.16M Buy
14,954
+2,658
+22% +$235K 0.04% 437
2021
Q3
$1.17M Buy
12,296
+1,051
+9% +$111K 0.04% 401
2021
Q2
$1.4M Buy
11,245
+3,873
+53% +$462K 0.05% 332
2021
Q1
$971K Buy
7,372
+2,175
+42% +$298K 0.04% 416
2020
Q4
$689K Buy
5,197
+4,542
+693% +$549K 0.04% 460
2020
Q3
$66.8K Buy
655
+19
+3% +$1.64K ﹤0.01% 1224
2020
Q2
$55.3K Hold
636
﹤0.01% 1254
2020
Q1
$36.9K Buy
636
+182
+40% +$14.8K ﹤0.01% 1293
2019
Q4
$42K Buy
454
+424
+1,413% +$37.3K ﹤0.01% 1415
2019
Q3
$2.71K Buy
+30
New +$3.42K ﹤0.01% 2420

Other funds holding EXAS

American Portfolios Advisors's EXAS Position: Q3 2022 in Review

American Portfolios Advisors increased its Exact Sciences (EXAS) stake by 0.07% in Q3 2022, buying an estimated $495 and bringing the position to 17,284 shares worth $562K. The position accounts for 0.02% of the portfolio, ranked #599.

American Portfolios Advisors first reported a position in EXAS in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.4M in Q2 2021. 480 funds tracked by Wall St. Rank hold EXAS as of Q3 2022.

  • American Portfolios Advisors held 17,284 shares of Exact Sciences worth $562K as of Q3 2022.
  • American Portfolios Advisors bought 12 Exact Sciences shares in Q3 2022, an estimated $495.
  • Exact Sciences made up 0.02% of American Portfolios Advisors's portfolio in Q3 2022, its #599 holding.
  • American Portfolios Advisors first reported a position in Exact Sciences in Q3 2019 and has held it in 13 quarters since.
  • American Portfolios Advisors's Exact Sciences position peaked at $1.4M in Q2 2021.
  • 480 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.